The c.1109C>T variant in MYOC is a missense variant predicted to cause substitution of Proline by Leucine at amino acid 370 (p.Pro370Leu). This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles. The REVEL score = 0.89, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function. A transgenic mouse model carrying human MYOC Pro370Leu (PMID: 36069958), and displaying reduced secretion of the Pro370Leu protein in vivo, exhibited a glaucoma phenotype (IOP elevation and retinal ganglion cell loss), meeting PS3. The Pro370Leu protein has also been assessed in these solubility, stability and secretion studies (PMIDs: 16466712,10545602, 11004290, 36579626, 15069026,16297911, 19234343, 17615537, 36267417, 21612213, 31270212), however, the same level of evidence was not met. 21 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 9490287, 9772276), which fulfilled PP1_Strong (≥7 meioses in >1 family). There were more family studies published than presented here. 15 probands with JOAG or POAG have been reported carrying this variant (PMIDs: 9345106, 9328473, 11774072, 28564705, 12447164, 22194650, 9792882, 23453510, 29540704, 30484747, 9490287, 9772276), which met PS4 (≥ 15 probands). There were more probands published than presented here. In summary, this variant met the criteria to receive a score of 15 and to be classified as pathogenic (pathogenic classification ≥ 10, adapted from PMID: 32720330) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v2, new_date_2024): PS3, PS4, PP1_Strong, PP3_Moderate, PM2_Supporting